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ABSTRACT
The clinical potential of umbilical cord blood-derived stem and progenitor cells has been demonstrated in
various animal and human transplantation studies. However, the need for increased numbers of appropriate
umbilical cord blood-derived cells continues to limit the development and success of these therapies. Ex vivo
expansion has been widely studied as a method to overcome this limitation. We describe the use of a clinically
relevant single-use, closed-system bioprocess capable of generating greater numbers of hematopoietic stem
and progenitor cells that maintain in vivo and in vitro developmental potential. In addition to expanded
numbers of CD34 cells, CD34CD38 cells, colony-forming cells, and long-term culture-initiating cells, the
bioprocess generated >3.3-fold more long-term nonobese diabetic/severe combined immunodeficient repop-
ulating cells (quantitatively determined using limiting dilution analysis) than present at input. Interestingly,
these cells were also capable of multilineage engraftment and were shown to maintain their engraftment
potency on a per long-term nonobese diabetic/severe combined immunodeficient repopulating cell basis
compared with input noncultured cells. The developmental capacity of bioprocess-generated cells was further
demonstrated by their ability to repopulate secondary nonobese diabetic/severe combined immunodeficient
recipients. In vitro lineage analysis confirmed that bioprocess-generated cells could differentiate into myeloid
and natural killer, B, and T cell lymphoid lineages. This in-depth analysis describes a bioprocess that generates
human hematopoietic stem and progenitor cells with conserved hematopoietic activity, establishes analysis
criteria for in vitro hematopoietic stem cell expansion studies, and serves as a foundation to test the therapeutic
utility of cultured hematopoietic stem cells in large animals and humans.
© 2006 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Umbilical cord blood (UCB) has been established
s an important source of hematopoietic stem cells
HSCs) for cell transplantation-based therapies [1].
fﬁcacy in decreasing the onset and recovery times of
eutrocytopenia and thrombocytopenia in patients
ith hematologic malignancies after high-dose che-
otherapy [2] and promise in the treatment of solidumors [3], nonmalignant hematologic diseases [4], n
020nd autoimmune diseases [5] have been demonstrated.
dvantages of using UCB include the low incidences
f graft-versus-host disease, lower risk to the donor,
ack of donor attrition, low viral transmission from
onor to patient, rapid availability of cryopreserved
CB units (median, 13.5-days), and the fact that it is
highly enriched source of HSCs [2,6,7].
Most transplantations using UCB have occurred
n a pediatric setting, reﬂecting a perspective that the
umber of cells that can be harvested from a typical
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Hematopoietic Stem Cell Expansion in a Closed-System Bioprocess 1021ord blood collection is limiting [8-11]. However,
ecent reports have indicated that the use of HLA-
ismatched UCB represents a safe and feasible alter-
ative for transplantation into adults who lack an
LA-matched bone marrow (BM) donor, even when
nfused at cell doses that are approximately 10-fold
ower (per kilogram) compared with typical BM dos-
ges [12,13]. Despite these promising developments,
he use of UCB grafts in children and adults results in
rolonged hematopoietic recovery [12-14], possibly
ontributing to the incidences of infection after trans-
lantation and patient mortality [15-17]. The best
redictor of patient survival and recovery in children
nd adults is cell dose, with a distinct advantage seen
n patients receiving higher cell numbers [18,19].
hese ﬁndings suggest that methodologies to increase
he number and appropriate types of UCB-derived
tem and progenitor cells before transplantation may
id in the applicability and success rate of such ther-
pies. This can be achieved through optimized proce-
ures for UCB collection, processing, and storage,
ransplantation of multiple cord blood units, and ef-
ective ex vivo HSC and progenitor cell expansion.
Several strategies have been pursued to achieve ex
ivo HSC and progenitor cell growth. Cultures have
een performed in open-system conﬁgurations in-
luding tissue culture dishes and ﬂasks and in closed-
ystems such as gas-permeable bags [20], stirred/spinner
asks [21,22], ﬂatbed perfusion bioreactors [23] and
n 3-dimensional scaffolds [24]. Many of these culture
echnologies have been tested clinically, thus demon-
trating the safety and feasibility of using expanded
SCs and their derivatives [25]. Although promising,
hese studies have not yet robustly demonstrated ad-
antageous hematologic recovery in comparison with
tudies performed with nonexpanded cells. A major
imitation of many ex vivo expansion studies is the lack
f an in-depth analysis of the in vitro and in vivo
evelopmental capacities of the generated cells. With-
ut this analysis, developing correlative relations be-
ween culture output and clinical efﬁcacy will remain
roblematic.
We and others have previously reported that cel-
ular and/or microenvironmental (ie, media compo-
ent) composition changes that occur during typical
x vivo culture can have signiﬁcant effects on the
xpansion of HSC and progenitor cell populations
26-30]. In our studies, we used a coordinated combi-
ation of subpopulation selection (ie, removal of cul-
ure-generated mature blood cell populations; lin
ells) and media dilution/exchange to control the pro-
uction of endogenously produced negative regula-
ors; manipulation of the concentration of these reg-
lators has been correlated with HSC output [26].
In addition to cell output potency, clinically rele-
ant cell production systems must consider the robust-
ess and safety of cellular products generated. To cranslate our culture methodology to a clinical setting
nd perform an in-depth analysis of the properties of
x vivo-generated cells in a condition that could be
ranslated to a clinical setting, we designed a single-
se, closed-system bioprocess that incorporates inline
ubpopulation selection and media dilution/exchange
apacities. We describe the capacity of this system to
enerate increased numbers (relative to input) of
CB-derived CD34 and CD34CD38 cells, colo-
y-forming cells (CFCs), long-term culture-initiating
ells (LTC-ICs), and long-term nonobese diabetic/
evere combined immunodeﬁcient (NOD/SCID) re-
opulating cells (LT-SRCs). Importantly, our data
uggest that the cells generated under these conditions
aintain their engraftment potency, on a per-LT-
RC basis, in comparison with noncultured lin cells.
aintenance of engraftment potential in vivo was
emonstrated by secondary NOD/SCID transplanta-
ion studies. The multilineage potential of these cells
as also demonstrated by using in vitro and in vivo
nalyses. This comprehensive analysis demonstrates
n amelioration of UCB sample properties after cul-
ure.
ETHODS
ell Sample Collection and Purification
UCB samples were collected from consenting do-
ors according to procedures accepted by the ethics
oards of Mt Sinai Hospital (Toronto, Ont, Canada),
oseph Brant Memorial Hospital (Burlington, Ont,
anada), and Credit Valley Hospital (Mississauga,
nt, Canada). The mononuclear cell fraction was ob-
ained by ﬁrst mixing the UCB sample with 10%
entastarch (Bistol-Myers Squibb Canada, Montreal,
ue, Canada) at a 1:5 volumetric ratio of cord blood
o pentastarch. The sample was then centrifuged at
0g for 10 min. Lineage-depleted (lin) cells were
solated from the mononuclear cell fraction by using
he StemSep system (Stem Cell Technologies, Van-
ouver, BC, Canada). This process depletes cells ex-
ressing CD2, CD3, CD14, CD16, CD19, CD24,
D56, CD66b, and glycophorin A.
ioprocess Assembly
The bioprocess used in these studies consists of 2
as-permeable cell culture bags (VueLife, American
luoroseal Corporation, Gaithersburg, Md) and a
ubpopulation selection element, which is responsible
or removing lin cells from culture (Figure 1A). The
ell culture bags used in these studies are sterile, ster-
lizable, and pyrogen free and have previously been
sed to grow HSCs for clinical applications [3]. The
esign is modular such that each component of the
ioprocess can be separated without exposing cell-
ontacting areas (ie, within the selection element and
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G. J. Madlambayan et al.1022ell culture bags) to environmental contaminants.
urther, the bioprocess is a single-use system, which
akes it attractive for clinical applications because the
isk of cell contamination due to repeated use is re-
oved.
The bioprocess was assembled in a sterile hood
ccording to the following procedure. First, the
ubpopulation selection element was fabricated by
btaining a 5-inch length of 1/8-inch inner diameter,
uorinated ethylene propylene lined Tygon tubing
igure 1. Bioprocess development. A, Schematic of the closed-
ystem bioprocess. The bioprocess consists of 2 cell culture bags
hat are joined through a subpopulation selection element. The
ubpopulation selection element is used to remove contaminating
in cells from culture. A peristaltic pump is used to control the ﬂow
ate of cells through the bioprocess. B, Validation of the subpopu-
ation selection element. Representative ﬂow cytometric plots show
he amount of lin cells present before (Bii) and after (Biii) selec-
ion. A negative control is also shown that was not labeled with the
nti-lin antibody (Bi). All axes on the ﬂow cytometric plots are
hown as log10 ﬂuorescence. C, Effect of increasing ﬂow rate on the
ecovery and purity of lin cells exiting the subpopulation selection
lement. Subpopulation selection was performed at 0.45  0.03
gravity induced ﬂow rate; n  4), 0.61  0.04 (n  4), 0.76  0.06
n  4), and 1.3  0.1 mL/min (n  5). At a ﬂow rate of 1.3  0.1
L/min, percent recovery and percent purity of lin cells were
aximized. *Signiﬁcant difference (P  .05) in percent recovery of
in cells versus all other ﬂow rates tested.Cole-Parmer, Vernon Hills, Ill) and ﬁlling the middle f-inch length with stainless steel selection beads (ap-
roximately 1.05  0.07 g; generously provided by
tem Cell Technologies). The beads were held in
lace with 2 0.12-0.15-inch diameter pieces of 80
esh, 430 stainless steel screening (generously pro-
ided by Stem Cell Technologies) that were formed to
t snugly into the inside diameter of the tubing (all
one with a custom-machined punch and form). The
/8-inch male luer ﬁttings (Cole-Parmer) were then
laced into each end of the tubing. The selection
lement was then autoclaved. Next, a 2-port 2- or
5-mL ﬂuorinated ethylene propylene culture bag
American Fluoroseal Corporation) was ﬁtted with
elf-sealing rubber septa (InterLink, American Fluo-
oseal Corporation) at each of its inlet ports (this bag
epresented the primary cell culture bag). A single
-port 3- or 7-mL bag was also ﬁtted with a rubber
eptum and served as the secondary culture bag. Two
-way stopcocks (Cole-Parmer) were attached to each
ale luer ﬁtting of the sterilized selection element. A
hreaded-lock cannula (American Fluoroseal Corpo-
ation) was then attached to each stopcock. The can-
ulae form a sterile connection with the self-sealing
ubber septa on the culture bags. The selection ele-
ent was then connected between the 2 culture bags.
he entire assembled product made up the bioprocess
Figure 1A).
ell Seeding and Culture
Isolated lin cells were cultured at 1 105 cells/mL
or 8 days in serum-free StemSpan medium (Stem
ell Technologies) supplemented with 100 ng/mL of
tem cell factor (SCF; R&D Systems, Minneapolis,
inn), 100 ng/mL of Flt-3 ligand (FL; R&D Sys-
ems), 50 ng/mL of thrombopoietin (TPO; R&D
ystems), and 1 g/mL of low-density lipoproteins
Calbiochem, La Jolla, Calif). The cell suspension was
njected into the primary cell culture bag (of appropri-
te volume) through the free self-sealing rubber septum
y using a sterile syringe attached to a threaded cannula.
he bioprocess was then maintained at 37°C in a hu-
idiﬁed atmosphere of 5% CO2 in air. Subpopulation
election (ie, to remove lin cells generated during
ulture) and media dilution/exchange were performed
t day 4 as previously described [26].
ubpopulation Selection and Media Dilution/
xchange in the Bioprocess
Cell selection in the bioprocess was performed in
similar manner to the StemSep system using the
eagents found in this cell selection kit. Brieﬂy, incu-
ation of the day 4 cultured cells with antibody cock-
ail and magnetic colloid (dextran-coated iron parti-
les) was carried out inside the primary cell culture
ag (as per the manufacturer’s instructions). This ef-
ectively attached the dextran-coated iron particles to
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Hematopoietic Stem Cell Expansion in a Closed-System Bioprocess 1023he lin cells. The cells were subsequently allowed to
ow through the subpopulation selection element,
hich was placed in an external magnetic ﬁeld, thus
llowing the iron-labeled lin cells to be retained in
he element. For ﬂow rate control, a peristaltic pump
as attached upstream of the primary cell culture bag
sing a septum/cannula connection (Figure 1A) and
sed to drive the cell solution through the selection
lement. Upon passing through the selection element,
he now puriﬁed lin cells were allowed to ﬂow di-
ectly into the secondary culture bag.
Media dilution/exchange was performed on the
nriched lin cells by ﬁrst removing the secondary cell
ulture bag from the selection element and then plac-
ng it into a 15- or 50-mL conical centrifuge tube
paper batting was used to stabilize the bag during
entrifugation). The tube was then centrifuged for 5
in at 200g, after which a cell pellet was visible at the
ottom of the culture bag. Medium was then removed
hrough the self-sealing septum using a sterile syringe
nd fresh medium was added through the same sep-
um. The cells were then placed back into the incu-
ator and allowed to grow until culture completion.
henotypic Analysis
Analysis of CD34 and CD34CD38 composi-
ion during culture was accomplished by resuspending
 104 freshly isolated lin cells or 5  105 cultured
ells in 100 L of ice-cold Hank’s balanced saline
olution (HBSS) containing 2% human serum (HBSS-
S). The cells were then incubated with saturating
mounts of CD34-phycoerythrin (PE), CD38-ﬂuo-
escein isothiocyanate (FITC), or appropriate isotype
ontrols (Beckman Coulter, Miami, Fla) for 30 min-
tes on ice and washed with HBSS-HS before analy-
is. Staining for lin markers was performed using an
ITC-labeled anti-dextran antibody (Stem Cell Tech-
ologies). Immediately after incubation with magnetic
extran beads, cells were stained with saturating
mounts of the anti-dextran antibody and washed in
BSS-HS. Cell viability was determined with 7-ami-
oactinomycine-D (Molecular Probes, Eugene, Ore)
o allow for the exclusion of nonviable cells during
nalysis. Flow cytometric analysis was performed with
Coulter EPICS XL with 4-Color Expo software or a
oulter EPICS Elite with Elite software (Beckman
oulter).
FC and LTC-IC Assays
Test cells (freshly isolated lin cells or cultured cells)
ere assayed for CFC content by plating 500 cells into
.5 mL of methylcellulose medium (MethoCult, Stem
ell Technologies) containing 1% methylcellulose in
scove’s Modiﬁed Dulbecco’s Medium, 30% fetal bo-
ine serum (FBS), 1% bovine serum albumin, 104 M
-mercaptoethanol, 2 mM l-glutamine, 50 ng/mL fCF, 10 ng/mL of granulocyte-macrophage colony-
timulating factor, 10 ng/mL interleukin (IL)-3, and 3
/mL erythropoietin. After 14 days of incubation,
uplicate or triplicate cultures were scored for CFC
ontent.
LTC-IC assays were performed by ﬁrst establish-
ng stroma cell feeders. Irradiated murine ﬁbroblasts
M2-10B4) were seeded into duplicate or triplicate
ells of collagen-coated 6-well plates in MyeloCult
edium containing 106 M freshly dissolved hydro-
ortisone (Stem Cell Technologies). A total of 2000
est cells was then seeded per well. After 5 weeks of
ulture at 37°C with weekly half-media exchanges,
he contents of each well were harvested and plated
nto methylcellulose media. LTC-IC content was
etermined by enumerating CFCs present after 14
ays.
ymphopoietic Assays
Natural killer (NK), B, and T cell progenitor dif-
erentiation potentials of bioprocess-cultured cells
ere assayed as previously described [31]. NK cell
ifferentiation was assessed by coculturing 5  104
xpanded cells/well on a conﬂuent layer of murine
S5 cells for 3 weeks. Before coculture, MS5 cells
ere seeded onto 96-well plates that were coated with
elatin. Cells were grown in RPMI 1640 medium
ontaining 10% FBS, 100 U/mL penicillin and strep-
omycin, 2 mM l-glutamine, 50 ng/mL SCF, 50
g/mL FL, 20 ng/mL IL-7 (R&D Systems), 20
g/mL IL-15 (R&D Systems), and 100 U/mL IL-2
R&D Systems). Half-media exchanges were done
eekly. Upon culture completion cells were stained
or CD3-FITC, CD56-PE, or appropriate isotype
ontrols (Beckman Coulter) to detect NK cells.
B cell differentiation was assayed by culturing 5 
04 expanded cells/well with MS5 cells for 2 weeks.
ells were maintained in RPMI 1640 containing 3%
BS, 100 U/mL penicillin and streptomycin, 2 mM
-glutamine, 50 M 2-mercaptoethanol, 50 ng/mL
CF, 100 ng/mL TPO, and 20 ng/mL IL-7 with
alf-media exchanges performed weekly. Upon cul-
ure completion cells were stained for CD19-FITC,
D34-PE, or appropriate isotype controls (Beckman
oulter) to detect B cells.
T cell differentiation was assayed by seeding 5 
04 expanded cells/well into a gelatin-coated 96-well
late coated with the deltalike-1 expressing OP9-DL1
ell line (kindly provided by J. C. Zúñiga-Pﬂücker,
unnybrook & Women’s College Health Sciences Cen-
re, Toronto, Ont, Canada). Cells were grown for up
o 7 weeks in RPMI 1640 medium containing 10%
S, 5% FBS, 50 M 2-mercaptoethanol, 50 ng/mL
CF, 50 ng/mL FL, 20 ng/mL IL-7, 20 ng/mL IL-15,
nd 100 U/mL IL-2 with half-media exchanges per-
ormed weekly. During the culture period, cells were
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G. J. Madlambayan et al.1024arvested weekly and stained with CD3-FITC, CD4-
E, CD8-FITC, or appropriate isotype controls (Beck-
an Coulter) to analyze progenitor cell differentiation
nto T cells.
ransplantation of Cells into NOD/SCID Mice
At 8-10 weeks of age, NOD/SCID mice were
ublethally irradiated (3.6 Gy) and test cell popula-
ions were transplanted by tail vein injection within 4
ours of irradiation as previously described [7]. After 8
eeks, mice were sacriﬁced using cervical dislocation
nd the BMs from the right and left femurs were
ollected and analyzed for human cell engraftment.
uman engraftment was determined by staining cells
ith saturating amounts of CD45-PE and HLA-abc-
ITC antibodies or isotype controls (Beckman
oulter) for 30 minutes on ice. Stained cells were then
ashed, resuspended in HBSS-HS containing pro-
idium iodide (Molecular Probes), and analyzed for
uman cell content using ﬂow cytometry. Trans-
lanted NOD/SCID mice were scored positive if
0.1% of the BM cells collected expressed human
D45. If human engraftment was detected, lineage
nalysis was performed on CD45 cells using CD19-
ITC, CD56-PE, CD33-PE, CD15-FITC, and CD14-
ITC (all from Beckman Coulter). For the secondary
ransplantation experiments, BM cells from engrafted
OD/SCID mice were collected and transplanted
nto newly irradiated mice. These experiments were
erformed by transplanting BM cells from a single
ouse into a single secondary recipient without pool-
ng. The contribution of LT-SRCs to engraftment
as calculated by ﬁrst showing a direct relation be-
ween cell dose and engraftment levels in mice. Each
ell dose was converted to equivalent LT-SRC num-
ers using the LT-SRC frequency calculated from the
imiting dilution analysis. Linear regression analysis
etween the dose of LT-SRCs transplanted and the
verage engraftment level for each dose was then per-
ormed to calculate the average contribution to en-
raftment per LT-SRC. All animal studies were per-
ormed after receiving approval from appropriate
nimal ethics boards.
tatistical Analysis
Signiﬁcant differences between test groups were
etermined using the Student t test. All data presented
re  standard error of the mean. Limiting dilution
nalysis to quantify LT-SRC expansion was per-
ormed by applying Poisson statistics to the single-hit
odel [7], with the frequency of LT-SRCs being
alculated using the maximum likelihood estimator
32]. In all cases, calculated chi-square values were not
igniﬁcant (P  .10), indicating that pooling of data
etween experiments was valid. cESULTS
losed-System Bioprocess Development
A single-use, closed-system bioprocess for the ex-
ansion of HSCs and progenitor cells was designed
Figure 1A) and a series of studies were performed to
est its performance. First, the ability of the subpopu-
ation selection element to remove mature lin cells
rom culture was evaluated. Flow cytometric analysis
onﬁrmed that the subpopulation selection element
as capable of efﬁciently removing lin cells from
ultured cells (Figure 1B). Cells exiting the selection
lement were highly enriched for lin cells with a
urity of 99.7 0.2% (n 4). Studies designed to test
he media dilution/exchange process (with input cell
umbers ranging from 5  105 to 2  106) demon-
trated that these manipulations could be performed
ithout signiﬁcant cell loss (average cell recovery,
8.9  0.7%; n  3).
During this testing, it was observed that lin cell
oss occurred in the system. The extent of cell loss was
uantiﬁed and found to be 34.1  13.1% (n  4).
ecause similar losses of total cells, CD34 cells,
D34CD38 cells, and CFCs were observed after
election, the nature of the losses was likely due to
onspeciﬁc binding in the selection column. To ab-
ogate the observed nonspeciﬁc cell loss, the effect of
ell suspension ﬂow rate through the selection ele-
ent was tested. Previous studies have demonstrated
hat ﬂow rate can signiﬁcantly affect the performance
f similar immunomagnetic selection columns [33,34].
n these experiments, a peristaltic pump was used to
stablish ﬂow rates of 0.45  0.03 (ﬂow rate when
onspeciﬁc loss was observed), 0.62  0.04, 0.78 
.06, and 1.3  0.1 mL/min. The results convincingly
howed that increasing ﬂow rate signiﬁcantly de-
reases nonspeciﬁc cell loss through the selection el-
ment. At the maximum tested ﬂow rate of 1.3  0.1
L/min, approximately 98.1  1.3% (n  5) of the
in cell population was recovered, which was signif-
cantly (P .05) better than all other ﬂow rates tested,
here recoveries of 65.5 6.5% (n 4), 75.9 3.2%
n  4), and 80.6  4.8% (n  4) were observed at
ow rates of 0.45 0.03, 0.62 0.04, and 0.78 0.06
L/min, respectively (Figure 1C). Importantly, all
ow rates tested yielded high levels of lin cell purity
Figure 1C). To minimize cell loss (and thus maximize
ell output), all subsequent studies were performed
ith the bioprocess operated at a ﬂow rate of 1.3
L/min.
obust Total and Progenitor Cell Expansion
n the Closed-System Bioprocess
To determine the overall effectiveness of the bio-
rocess to grow hematopoietic progenitor cells, UCB
in cells were subjected to 8-day cultures in which
ells were exposed to subpopulation selection and me-
d
t
p
1
v
8
ﬁ
c
.
c
n
L
i
(
e
3
C
t
H
p
p
w
t
w
t
B
o
r
c
C
C
m
t
m
o
c
i
3
7
d
i
t
m
c
e
p
p
f
(
w
a
[
F
c
c
c
e
(
7
i
F
i
t
C
C
4
Hematopoietic Stem Cell Expansion in a Closed-System Bioprocess 1025ia dilution/exchange at day 4 to control the produc-
ion of endogenously produced negative regulators as
reviously described [26]. Input cell densities were
 105 cells/mL, resulting in a range of culture
olumes between 2.3 and 24.5 mL. At the end of the
-day culture period, analysis of kinetic growth pro-
les revealed that the bioprocess could effectively in-
rease the absolute numbers of total cells (n 11; P
009), CD34 cells (n  7; P  .01), CD34CD38
ells (n  7; P  .02), CFCs (n  5; P  .00001;
ormalized to account for input variability), and
TC-ICs (n  4; P  .002; normalized to account for
nput variability) in comparison with input numbers
Figure 2). Overall, the bioprocess yielded average
xpansions of 24.6  3.6, 30.8  7.2, 105.5  31.6,
1.3 5.8, and 32.6 7.5 for total cells, CD34 cells,
D34CD38 cells, CFCs, and LTC-ICs, respec-
ively (Figure 3).
igure 2. Kinetic analysis of the absolute numbers of hematopoietic
ells generated and recovered from the bioprocess over the 8-day
ulture period. Puriﬁed UCB lin cells (1  105 cells/mL) were
ultured for 8 days with subpopulation selection and media dilution/
xchange occurring at day 4. Kinetic growth proﬁles for total cells
A; n  11), CD34 cells (A; n  7), CD34CD38 cells (A; n 
), CFCs (B; n  5), and LTC-ICs (C; n  4) are shown. Absrndicates absolute.uman Cell Engraftment in NOD/SCID Mice
To determine the engraftment potential of bio-
rocess-generated cells, test populations were trans-
lanted into NOD/SCID mice and analyzed at 8
eeks for LT-SRC content. Analysis using ﬂow cy-
ometry demonstrated that bioprocess-generated cells
ere capable of long-term engraftment as shown by
he presence of human CD45HLA-abc cells in the
M of recipient mice (Figure 4A). Further analysis
f the CD45 human population in the mouse BM
evealed that bioprocess-cultured cells were also
apable of multilineage engraftment with CD14
D33 and CD15CD33 myeloid and CD19
D56 lymphoid lineages readily detected (3 of 3
ice tested; Figure 4B).
Limiting dilution analysis was performed to quan-
ify LT-SRC expansion. In this study NOD/SCID
ice received transplants of fresh lin cells (n  52)
r bioprocess-cultured cells (n  57) over a range of
ell doses (Figure 4C). The frequency of LT-SRCs
n fresh lin cells was found to be 1 in 49 990 (1 in
5 640 to 71 780) and increased to 1 in 15 300 (1 in
010 to 22 430; frequency adjusted to day 0) after 8
ays in culture. This indicated that LT-SRC numbers
ncreased by 3.3-fold after culture.
Our extensive limiting dilution analysis allowed us
o gather statistically signiﬁcant data on the engraft-
ent potency of bioprocess-cultured cells, assessed by
omparing the level of human CD45HLA-abc cell
ngraftment in the BM of NOD/SCID mice trans-
lanted with fresh (noncultured) lin cells or an ex-
anded cell population. In these experiments, it was
ound that human cell engraftment for fresh lin cells
Figure 4Di) and cultured cells (Figure 4Dii) increased
ith the cell dose transplanted per mouse, indicating,
s has been previously reported for noncultured cells
35], a direct relation between these variables. Linear
igure 3. Expansion (relative to input lin cells) of total and progen-
tor cells in the bioprocess. Fold expansion values were calculated for
otal cells (n 11), CD34 cells (n 7), CD34CD38 cells (n 7),
FCs (n 5), and LTC-ICs (n 4). Input CD34, CD34CD38,
FC, and LTC-IC numbers were 36.3  17.3, 9.6  6.3, 16.7 
.4, and 2.9  2.0 per 100 starting lin cells, respectively.egression analysis, combined with LT-SRC frequen-
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G. J. Madlambayan et al.1026ies obtained from limiting dilution analysis, allowed
s to calculate that the average contribution to percent
uman cell engraftment from each LT-SRC were
.9% and 7.5% for fresh and cultured cells, respec-
ively. These results demonstrated that the bioprocess-
enerated LT-SRC population maintains engraftment
igure 4. Bioprocess-generated human cell engraftment in NOD/
CID mice. A, Representative ﬂow cytometric plots show the pres-
nce of human CD45HLA-abc cells (Aiii) after 8 weeks in NOD/
CID mice injected with bioprocess-cultured cells. Also shown are
typical isotype control mouse (Ai) and a control mouse that did not
eceive cells (Aii). B, Analysis of engrafted human CD45 cells in
he BM of NOD/SCID mice demonstrates their multilineage de-
elopmental potential. Representative ﬂow cytometric dot plots
how human myeloid (CD14, CD15, and CD33; Bi-ii) and lym-
hoid (CD19 and CD56; Biii) lineages in the BM of engrafted mice.
nalysis was done by gating on the CD45 population. C, Results
f limiting dilution analyses used to calculate the frequency of
T-SRCs present in noncultured lin cells (Ci) and bioprocess-
enerated cells (Cii; adjusted to day 0 equivalents). The LT-SRC
requencies calculated from the maximum likelihood estimator are
hown on the plots. D, Percent engraftment of human cells in
OD/SCID mice is directly correlated to cell dose for fresh lin
ells (Di) and bioprocess-generated cells (Dii). The average percent
ngraftment for each cell dose is marked with a solid line. Symbols
*) represent individual mice. Gating on ﬂow cytometric plots was
et based on 99.9% negativity for the isotype controls established
or each sample. All axes on the ﬂow cytometric plots are shown as
og10 ﬂuorescence. IgG indicates immunoglobulin G.otency similar to that seen with noncultured LT-SRCs. sTo conﬁrm that the bioprocess-generated cells
ere capable of in vivo self-renewal, whole BM from
engrafted mice, initially injected with cells from the
ame expanded population, were collected and trans-
lanted into 3 secondary recipients (1-to-1 transplan-
ation without pooling). Flow cytometric analysis of
econdary mice 8 weeks after transplantation resulted
n the detection of human cells in 2 of the 3 secondary
ice injected. Primary mice with engraftment levels
f 12.6% and 71.2% resulted in secondary mouse
ngraftment levels of 0.1% and 1.2%, respectively
data not shown). The primary mouse that did not
roduce secondary engraftment had a percent engraft-
ent level of 21.8%.
dentification of Lymphoid Progenitors in
ioprocess-Cultured Cells
The presence of primitive myeloid progenitor
ells was convincingly shown with the CFC and
TC-IC assays. To determine if bioprocess-gener-
ted cells also maintained lymphoid developmental
otential, output cells were tested for their ability to
enerate NK (n  6), B (n  6), and T (n  6) cells.
K cell potential was demonstrated by coculturing
xpanded cells with the murine MS5 cell line in the
resence of SCF, FL, IL-7, and IL-15. After 3 weeks
f coculture, the emergence of CD3CD56 NK
ells was observed, indicating the presence of NK cell
rogenitors in bioprocess-generated cells (6 of 6 cul-
ures tested; Figure 5A). Interestingly, a small popu-
ation of CD3CD56 NK cells could be observed in
he expanded cell population, suggesting that the cul-
ure conditions used in this study supported the gen-
ration of NK cells. B cell potential was assessed by
oculture on MS5 cells in the presence of SCF, TPO,
nd IL-7. In these experiments, 2-week culture re-
ulted in the generation of CD19CD34 B cells,
onclusively demonstrating the presence of B cell pro-
enitors in bioprocess-generated cells (6 of 6 cultures
ested; Figure 5B). Analysis of expanded cells showed
hat no CD19CD34 B cells were present. T cell
evelopmental potential of expanded cells was deter-
ined by using a recently described coculture system,
ased on the murine stomal cell line OP9 engineered
o express the Notch ligand deltalike-1 (OP9-DL1)
36]. Reports have shown that human hematopoietic
rogenitors from UCB and BM can differentiate into
lymphocytes when cultured with the OP9-DL1 cell
ine in a manner similar to that seen in the thymus
31,37]. We extended the use of the OP9-DL1-based
ymphopoietic assay to our bioprocess-generated cells.
pon coculture, the expanded cell population dis-
layed kinetic phenotype changes analogous to nor-
al T cell differentiation (6 of 6 cultures tested; Fig-
re 5C). After 2 weeks, the cells express CD4 but not
D8. Subsequent analysis at 3 and 4 weeks demon-trated the progressive emergence of CD4CD8
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Hematopoietic Stem Cell Expansion in a Closed-System Bioprocess 1027ouble positive cells and a concomitant increase in CD3
xpression, characteristic of the phenotypic changes as-
ociated with normal thymocytes. Before coculture, no
D4CD8 or CD3CD8 T cells were present in
he expanded cell population. When longer culture
eriods were tested, analysis revealed the further pro-
ression of cells into CD4CD8 and CD4CD8
ingle positive T cells; however, this was not observed
n all experiments. Together these data conﬁrmed that
ioprocess-generated cells do not have compromised
ymphoid potential and maintain the ability to differen-
iate into phenotypically deﬁned NK, B, and T cells.
ISCUSSION
Observations that increased cell doses correlate
ith better patient outcomes suggest that the ability to
xpand HSCs and progenitor cells before transplan-
ation may improve patient recovery. Although it has
ot been conclusively shown which target cells are
igure 5. Lymphoid potential of bioprocess-generated cells. The
resence of lymphoid progenitors in the expanded cell population
as evaluated using phenotypic assays. A, B, Upon coculture with
he MS5 cell line and appropriate cytokines, expanded cells were
ble to form CD3CD56 NK cells (A; n  6) and CD19CD34
cells (B; n  6). C, Coculture of expanded cells with the OP9-
L1 cell line resulted in the generation of phenotypically deﬁned
cells (n  6). Kinetic analysis of CD3, CD4, and CD8 expression
or up to 7 weeks shows the phenotypic maturation of progenitor
ells into T cells. Flow cytometric plots are representative of inde-
endent experiments. Gating on ﬂow cytometric plots was set based
n 99.9% negativity for the isotype controls established for each
ample. A population was scored positive if the changes in the
xpression levels of surface markers associated with each cell type
ere above those established by the isotype controls. All axes on the
ow cytometric plots are shown as log10 ﬂuorescence.esponsible for improved outcome, it is generally be- sieved that enhancement of stem and progenitor cell
ctivities and maintenance of multilineage developmen-
al capacity are minimum requirements. The present
ata demonstrate the use of a clinically relevant, single-
se, closed-system bioprocess for the ex vivo expan-
ion of HSCs and progenitor cells. The expansion of
hese cells was concomitant with conserved engraft-
ent potency of the repopulating stem cell population
nd maintained multilineage potential as shown by the
bility of cultured cells to produce myeloid and lym-
hoid populations.
Recent clinical trials have been inconclusive with
espect to enhancement of hematologic recovery from
ultured UCB [25,38,39]. However, due to an incom-
lete analysis regarding the utility of the culture meth-
dologies to maintain or expand LT-SRCs and appro-
riate downstream progenitors, it remains possible
hat transplant potency was not maintained (or was
ven lost [40]) during in vitro culture. Using rigorous
imiting dilution analysis, the present results quanti-
atively demonstrate that 3.3-fold more LT-SRCs
ere generated in the bioprocess. Importantly, the
ioprocess-generated LT-SRCs maintained their en-
raftment potency, on a per-LT-SRC basis, in com-
arison with noncultured cells and were capable of
ultilineage engraftment. It was also demonstrated
hat the cultured cells maintained their long-term en-
raftment potential in vivo as shown by their ability to
epopulate secondary recipients. Additional secondary
ransplantation experiments (and multilineage analy-
es), using expanded cells from different cord blood
reparations, should be performed to show the repro-
ucibility of these results on a per-cord blood basis.
omparing the frequency of successful secondary
ransplantations between expanded and nonexpanded
ord blood samples would provide a method of quan-
itatively demonstrating maintenance of engraftment
otential in vivo. This type of in-depth in vivo analysis
s necessary not only to demonstrate the repopulating
bility of cultured stem and progenitor cells but also to
llow the phenotypic and functional properties of
hese cells to be correlated with clinical outcome.
It is clear that successful HSC transplantation also
equires the generation of a competent immune sys-
em that includes the generation of lymphoid effector
ells [41]. This motivated testing the ability of biopro-
ess-generated cells to differentiate directly into NK,
, and T cell populations. In these studies, the use of
n vitro lymphopoietic assays showed that bioprocess-
enerated cells could produce phenotypically deﬁned
K, B, and T cells. Interestingly, the presence of
hese cells may also augment engraftment because it
as been shown that lymphoid cell populations can
revent the unwanted occurrences of graft-versus-
ost disease, infections, and leukemia relapse or facil-
tate graft-versus-tumor effects [42]. Of interest, these
tudies are the ﬁrst to show the presence of progenitor
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G. J. Madlambayan et al.1028ells in an expanded UCB population that have the
bility to differentiate into T cells using the OP9-DL1
ell line. The ability to differentiate T cells in vitro
ill allow us to further study T cell development from
xpanded UCB cells and establish functional assays to
est culture-generated lymphoid activity.
The subpopulation selection process was shown to
fﬁciently remove contaminating lin cells from cul-
ure, which we previously demonstrated are a source
f inhibitory factors that prevent HSC expansion [26].
y increasing cellular ﬂow rate through the selection
lement, we were able to eliminate nonspeciﬁc cell
oss, increasing overall lin cell recovery, without de-
reasing purity. This may be explained by the de-
reased residence time of cells within the subpopula-
ion selection element, effectively preventing cells from
ontacting nonspeciﬁc binding sites. It is also possible
hat the slower ﬂow rates allowed for “pooling” or
trapping” of cells within the pores of the selection
lement. The ability to minimize cell loss is important
o ensure optimal recovery of the stem and progenitor
ells generated in the bioprocess. Previous work, using
similar immunomagnetic selection column, also
howed that ﬂow rate could signiﬁcantly affect non-
peciﬁc cell loss, thus supporting the present ﬁndings
33,34].
It has been reported that signiﬁcant variability
xists in the numbers and types of cells obtained from
ypical cord blood collections [43] and in their expan-
ion capacities [44,45]. The modularity of the biopro-
ess may be useful to address some of this sample
eterogeneity because culture volumes, medium sup-
lementation, and other bioprocesses parameters can
e modiﬁed without compromising the closed culture
onditions; ongoing studies are evaluating parameters
hat would assist in the standardization of these oper-
ting conditions.
In its current conﬁguration, the bioprocess re-
oves all mature lin cells from culture. Knowledge
hat some mature cells secrete factors known to stim-
late HSC growth [46,47] suggests that the gross
emoval of mature lin cells may remove a popula-
ion(s) of cells whose secreted products would enhance
SC expansion. We are currently beginning to screen
he phenotypic identity of input and culture-produced
nhibitory and stimulatory cells, with the goal of elim-
nating inhibitory cells and concomitantly enriching
or stimulatory cells in culture. By using this approach
o control the types of endogenous factors that are
ecreted in culture, it may be possible to create envi-
onments that are self-stimulating (ie, generate their
wn stimulatory factors), thus decreasing the need to
dd costly cytokines to culture media.
The studies herein describe the use of a clinically
elevant bioprocess capable of efﬁciently and robustly
xpanding transplantable UCB-derived HSCs and
rogenitor cells. Establishing the foundation for anutomatable, closed-system bioprocess should prove
o be valuable for the development and implementa-
ion of clinical HSC-based transplantation therapies.
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